捷成股份(300182.SZ):已形成短劇、短視頻、長視頻、影視宣傳視頻物料等多元綜合內容梯隊
格隆匯5月9日丨捷成股份(300182.SZ)於2024年5月8日召開業績説明會,就“公司有做微短劇嗎?”,公司回覆稱,公司結合自身的渠道優勢,積極佈局短劇微短劇方面的內容集成與流量運營生態。公司已形成短劇、短視頻、長視頻、影視宣傳視頻物料等多元綜合內容梯隊,並廣泛匯聚MCN、流量大V賬號,開展內容推流與結算分賬,搭建傳播矩陣。公司於2023年度參與發行了包括《是!老闆》、《王妃萬福》、《奇妙請微笑》等多部精品短劇,其中《孤軍12時》榮獲第十屆亞洲微電影藝術節優秀創作作品獎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.